📰 Matthias Evers News
Page 3 - Matthias Evers News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Matthias Evers. Real-time updates on events, politics, business and more.
September 27, 2023
EQS-News: Evotec SE / Key word: Miscellaneous Evotec SE: Launch of partnering agreement to strengthen biotech innovators in shared R&D economy 27.09.2023 /...
September 27, 2023
EQS-News: Evotec SE / Key word(s): MiscellaneousEvotec SE: Launch of partnering agreement to strengthen biotech innovators in shared R&D economy 27.09.2023 / 07:30 CET/CESTThe issuer is solely responsible for the content of this announcement.  LABCENTRAL, BIOLABS, MBC BIOLABS PARTNER WITH EVOTEC TO SUPPORT...
September 27, 2023
EQS-News: EVOTEC SE / Key word(s): Miscellaneous Evotec SE: Launch of partnering agreement to strengthen biotech in...
September 27, 2023
LABCENTRAL, BIOLABS, MBC BIOLABS PARTNER WITH EVOTEC TO SUPPORT BIOTECH INNOVATORS THROUGH CRITICAL INFLECTION POINTSAGREEMENT LEVERAGES EVOTEC'S INTEGRATED END-TO-END SHARED R&D PLATFORM TO ENABLE GREATER ACCESS TO INDUSTRY-GRADE CAPABILITIES AND ...
May 9, 2023
EQS-News: Evotec SE / Key word: Miscellaneous Just – Evotec Biologics launches tech partnership for biosimilars development and commercial manufacturing 09.05.2023 / 20:07... | May 9, 2023
May 9, 2023
Just - Evotec Biologics Launches Tech Partnership for Biosimilars Development ...
May 9, 2023
JUST - EVOTEC BIOLOGICS AND SANDOZ JOIN FORCES TO DEVELOP AND MANUFACTURE A DEFINED PORTFOLIO OF BIOSIMILAR MOLECULESJUST - EVOTEC BIOLOGICS TO RECEIVE DOUBLE-DIGIT-MILLION UPFRONT, FUTURE PAYMENTS DEPENDENT
May 9, 2023
EQS-News: EVOTEC SE / Key word(s): Miscellaneous Just Evotec Biologics launches tech partnership for biosimilars development and com...
August 13, 2022
Evotec SE (OTCPK:EVOTF) Q2 2022 Earnings Conference Call August 11, 2022, 8:00 AM ET Company Participants Dr.
August 11, 2022
BASE BUSINESS, NEW AND EXTENDED ALLIANCES DRIVE 24% GROWTHJUST - EVOTEC BIOLOGICS IN BUILD-UP PHASE - INVESTMENT ON TRACKACQUISITION EXPANDS CAPABILITIES AND EXPERTISE IN CELL THERAPYGUIDANCE FOR FULL-YEAR